Company 4basebio PLC

Equities

4BB

GB00BMCLYF79

Biotechnology & Medical Research

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sales per Business

Sales per region

Ratings for 4basebio PLC

EPS Revisions

Annual profits - Rate of surprise

Sector Other Biotechnology & Medical Research

Market Closed - London S.E. Other stock markets 11:35:12 2024-04-24 am EDT			5-day change	1st Jan Change
1,070 ^GBX	+2.39%		0.00%	+57.35%

Apr. 10	4basebio to supply synthetic DNA for mRNA vaccine program	AN
Apr. 10	4Basebio plc Announces the Supply of Its opDNA? DNA Products into Tier 1 Pharma Client's Vaccine Program	CI

4basebio PLC is a United Kingdom-based specialist life sciences company. It is focused on therapeutic deoxyribonucleic (DNA) for cell and gene therapies and DNA vaccines and providing solutions for effective and safe delivery of these DNA based products to patients. It is engaged in the manufacturing and supplying of application specific synthetic DNA for research, therapeutic and pharmacological use and develop non-viral vectors for the efficient delivery of payloads. It has technology in the fields of DNA synthesis and payload delivery, which enables it to manufacture both synthetic DNA constructs and messenger ribonucleic acid (mRNA) and develop vectors for cell and tissue-specific delivery for a range of applications. Its applications include AAV and Lentivirus viral vectors; mRNA vaccines and therapeutics, Genome editing; DNA vaccines, and Hermes non-viral delivery. It is also focused on exploiting intellectual property in the field of cell and gene therapies and DNA vaccines.

Number of employees: 78

GBP in Million	2021	Weight	2022	Weight	Delta
Synthetic DNA and RNA Products 92.5 %	0	95.0 %	0	92.5 %	-22.74%
Licences and Royalties 7.5 %	0	5.0 %	0	7.5 %	+17.65%

GBP in Million	Weight	Weight	Delta
United States 60.4 %	69.5 %	60.4 %	-31.06%
Europe 31.7 %	24.3 %	31.7 %	+3.66%
Rest of World 7.8 %	6.2 %	7.8 %	0.00%

Managers	Title	Age	Since
Heikki Lanckriet CEO	Chief Executive Officer	47	20-12-21
David John Roth DFI	Director of Finance/CFO	56	20-12-21

Members of the board	Title	Age	Since
Joseph Fernández BRD	Director/Board Member	64	-
David John Roth DFI	Director of Finance/CFO	56	20-12-21
Hansjörg Plaggemars BRD	Director/Board Member	53	-
Tim McCarthy McCarthy CHM	Chairman	68	20-12-21
Heikki Lanckriet CEO	Chief Executive Officer	47	20-12-21
María del Pilar de la Huerta Martínez BRD	Director/Board Member	55	-

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	12,805,208	3,893,037 ( 30.40 %)	0	30.40 %

Name	Equities	%	Valuation
Wilhelm Konrad Zours 51.58 %	6,604,357	51.58 %	80 M p
Deutsche Balaton AG 46.59 %	5,965,921	46.59 %	72 M p
2INVEST AG 28.62 %	3,665,242	28.62 %	44 M p
Heikki Lanckriet 9.458 %	1,211,060	9.458 %	15 M p
Joseph Fernández 3.463 %	443,429	3.463 %	5 M p
Aramea Asset Management AG 1.119 %	143,333	1.119 %	2 M p
Deutsche Bank AG (Private Banking Germany) 0.4035 %	51,666	0.4035 %	626 564 p
David John Roth 0.000000 %	0	0.000000 %	- p

4basebio Plc

25 Norman Way Over

CB24 5QE, Cambridge

+44 1223 967 943

http://www.4basebio.com

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
4BASEBIO PLC	+57.35%	166M
IQVIA HOLDINGS INC.	+4.09%	43.43B
LONZA GROUP AG	+47.81%	41.69B
MODERNA, INC.	+9.45%	41.31B
CELLTRION, INC.	-10.92%	27.14B
ICON PUBLIC LIMITED COMPANY	+9.32%	25.28B
ALNYLAM PHARMACEUTICALS, INC.	-24.87%	18.47B
MEDPACE HOLDINGS, INC.	+29.70%	12.59B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	+1.28%	12.33B
UNITED THERAPEUTICS CORPORATION	+7.78%	11.03B

Other Biotechnology & Medical Research